<DOC>
	<DOCNO>NCT01860508</DOCNO>
	<brief_summary>PFS</brief_summary>
	<brief_title>A Study PC Sequential Pemetrexed Single Drug Maintenance Treatment NSCLC Related Predictive Biomarkers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>.≥65 year PS 2 Patients diagnosed histologic , cytologic diagnosis IV nonsmall cell lung cancer Patients receive chemical therapy receive targeted therapy , evidence show patent PD Presence least one index lesion measurable CT scan MRI leucocyte ≥ 3.5×109/L neutrophil ≥ 1.5×109/L platelet ≥ 80×109/L Hemoglobin ≥ 9g/L ALT AST ≤ 2.5×ULN , Tbil≤ 1.5×ULN BUN≤ 1.5×ULN Signed write informed consent squamous carcinoma small cell lung cancer Patients allergic pemetrexed Patients receive chemotherapy Uncontrolled acute infection .Uncontrolled pleural effusion Severe symptomatic heart disease Severe infection metabolic disfunction Patients malignant tumor Uncontrolled brain metastasis Patients accept clinical trial Female patient pregnant lactation period , patient without contraception Mental disorientation disorder Glucocorticoids taboo</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Progression free Survival</keyword>
</DOC>